Side Effects of Brolucizumab.
Reads0
Chats0
TLDR
In this article, a new anti-VEGF agent, brolucizumab, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for the treatment of wet age-related macular degeneration.Abstract:
Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome and provided an evolution in the treatment of retinal disease. The current four anti-VEGF drugs - pegaptanib, ranibizumab, aflibercept, and bevacizumab - have been administered for many years. A new anti-VEGF agent, brolucizumab, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for the treatment of wet age-related macular degeneration. Brolucizumab is a novel single-chain fragment variable antibody that inhibits all isoforms of VEGF-A and has been suggested to have more tissue penetration. Despite all the benefits, there are some reports of serious side effects that need to be understood in managing patients. Brolucizumab has been reported to cause occlusive retinal vasculitis in the setting of intraocular inflammation, which has not been seen in other anti-VEGF medications. A PubMed and Scopus search was performed and all article types were included. In the present article, we have reviewed the reported side effects of brolucizumab.read more
Citations
More filters
Journal ArticleDOI
GSK3 Is a Central Player in Retinal Degenerative Diseases but a Challenging Therapeutic Target
TL;DR: The literature on the role of GSK3 on the main cellular functions reported as deregulated during retinal degeneration, such as glucose homeostasis which is critical for photoreceptor survival, or oxidative stress, a major component of retina degeneration are summarized.
Journal ArticleDOI
The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
TL;DR: Blucizumab was non-inferior to other anti-VEGF agents in improving BCVA and decreasing CSFT but it caused more serious ocular adverse events which is worthy of special attention by ophthalmologists.
Journal ArticleDOI
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial
Ryusaburo Mori,Shigeru Honda,Fumi Gomi,Akitaka Tsujikawa,Hideki Koizumi,Haruka Ochi,Shino Ohsawa,Annabelle A. Okada +7 more
TL;DR: TENAYA as mentioned in this paper evaluated the 1-year efficacy, durability, and safety of faricimab versus aflibercept in patients with neovascular age-related macular degeneration (nAMD) enrolled in the Japan subgroup of the TENDAYA trial.
Journal ArticleDOI
Erratum: Side Effects of Brolucizumab
TL;DR: In this article , the authors correct the article DOI: 10.18502/jovr.v16i4.9757 and present a new version of the article.
Journal ArticleDOI
Three Major Causes of Metabolic Retinal Degenerations and Three Ways to Avoid Them
TL;DR: In this paper , the authors provide a unified background, common prevention and treatment rationale for diabetic retinopathy and glaucoma and identify the mechanisms through which these actions protect the retina.
References
More filters
Journal ArticleDOI
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wan-Ling Wong,Xinyi Su,Xiang Li,Chui Ming Gemmy Cheung,Ronald Klein,Ching-Yu Cheng,Tien Yin Wong +6 more
TL;DR: In this article, the authors did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013, using retinal photographs and standardised grading classifications.
Journal ArticleDOI
Pegaptanib for Neovascular Age-Related Macular Degeneration
TL;DR: Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration.
Journal ArticleDOI
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more
TL;DR: It is demonstrated that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.
Journal ArticleDOI
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F. Martin,Maureen G. Maguire,Stuart L. Fine,Gui-Shuang Ying,Glenn J. Jaffe,Juan E. Grunwald,Cynthia A. Toth,Maryann Redford,Frederick L. Ferris +8 more
TL;DR: Ranibizumab and bevacizumAB had similar effects on visual acuity over a 2-year period and switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2.
Journal ArticleDOI
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
TL;DR: Assessing long-term outcomes 7 to 8 years after initiation of intensive ranibizumab therapy in exudative age-related macular degeneration patients found one third of patients demonstrated good visual outcomes, whereas another third had poor outcomes.
Related Papers (5)
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration.
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
Claudio Campa,Simon P. Harding +1 more